Overview

A Trial of HR18034 in Inguinal Hernia Repair

Status:
Recruiting

Trial end date:
2021-05-30

Target enrollment:

Participant gender:

Summary

Phase I, randomized, double-blind, comparator-controlled study to assess the safety, PK, and efficacy of single postsurgical application of HR18034 compared with Naropin®

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Ropivacaine